Luke O’Neill joins Open Orphan spin-off ahead of pharma firm’s IPO

Ambitions are high for Poolbeg Pharma, which will develop drugs to fight infectious diseases

Professor Luke O’Neill, the immunologist, is a non-executive director of Poolbeg Pharma and a member of the company’s scientific advisory board. Picture: Barry Cronin